Singapore Clinical Trial: A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants

Singapore, Sept. 7 -- The Health Sciences Authority received information related to the study titled 'A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the ef... Read More

Singapore Clinical Trial: A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Singapore, Sept. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigat... Read More

Singapore Clinical Trial: A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4167586 in Participants with Obesity or Overweight who are Otherwise Healthy.

Singapore, Sept. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate t... Read More

Temasek, London-listed Seraphim lead spacetech startup Pixxel's Series C

New Delhi, Sept. 7 -- Bengaluru-headquartered space technology startup Pixxel said on Monday that it had raised $100 million (around Rs 944 crore) in a Series C funding round co-led by Singapore's sov... Read More

Kelly Osbourne reveals she hid her weight loss with wig at GrammysPublished on: September 7, 2026 10:01 AM

Pakistan, Sept. 7 -- Kelly Osbourne has revealed that she did not notice her dramatic weight loss until she wore a wig to this year's Grammy Awards to conceal her thin appearance. The TV personality ... Read More

No tiger, just AI: Andhra man made to do 50 squats as punishment

Andhra Pradesh, Sept. 7 -- Shivers ran down the villagers of Kavali in Nellore district, Andhra Pradesh, who thought a giant tiger was on the prowl. An image of the 'tiger' perched on a hill was shar... Read More

Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, Sept. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safet... Read More

Singapore Clinical Trial: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Singapore, Sept. 7 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) M... Read More

Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, Sept. 7 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig i... Read More

Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, Sept. 7 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig i... Read More

• ««
• «
• 220
• 221
• 222
• 223
• 224
• 225
• 226
• 227
• 228
• 229
• »
• »»